Although inhibitors to Ras/MAPK signaling, including BRAF V600E and KRAS G12C inhibitors, are approved for other cancers, the Ras/MAPK pathway mutations observed in resistance to FLT3 inhibitors are not sensitive to these agents [78, 79]. Here, FLT3 is linked to cancer.